Ketan Mehta
executive
Ketan Mehta is the chief executive of Tris Pharma, a company involved in developing new pain management therapies. He has overseen the development of cebranopadol, a novel painkiller that activates specific opioid receptors with a lower risk of addiction compared to traditional opioids.
Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
24,677
Power
981$
Sentiment
7.00
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 7.00 | 0.04% | +0% | 67,886,011 | 24,677 | $2,700,000 | 981$ |
| Totals | 1 | 67,886,011 | 24,677 | $2,700,000 | 981$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Ketan Mehta is the chief executive of Tris Pharma.
7
Gregory Scherrer
Anthony Dickenson
Jeffrey Mogil
Amanda Williams
Mark Hutchinson
Christopher Eccleston
David Altshuler
David Andersson
The Guardian: Painkillers without the addiction? The new wave of non-opioid pain relief | Science